Regenacy Pharmaceuticals, Inc.

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.